Nanoscope Therapeutics Inc.
Chaweewan Ruechai has a Bachelor of Business Administration in Accounting and Finance from the University of Texas at Tyler and an Associate of Science in Accounting from Houston Community College. With a background in accounting and finance, Chaweewan has held various roles such as Accounting Manager at Nanoscope Therapeutics Inc., Tax Associate at Decision Financial Services, Inc., Payroll Assistant at Thai House Restaurant, Accounting Administrator at Gold Simple & Secure, and Finance Administrator at Hard Rock Hotel Pattaya. Throughout these roles, Chaweewan has demonstrated proficiency in managing accounts payable, bank reconciliations, payroll processing, inventory control, financial tracking, and contract management with a high level of accuracy and attention to detail.
Nanoscope Therapeutics Inc.
1 followers
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa